NCT02108483 is a Phase 1 clinical trial of dapsone gel in Healthy Volunteers, sponsored by Almirall, S.A..

Who is sponsoring NCT02108483?

NCT02108483 is sponsored by Almirall, S.A..

What drugs are being tested in NCT02108483?

Interventions in NCT02108483: dapsone gel, dapsone gel vehicle.

What condition does NCT02108483 study?

NCT02108483 studies Healthy Volunteers.

Is NCT02108483 still recruiting?

NCT02108483 is currently completed. Last updated 5 October 2018.

Last reviewed 2018-10-05 · How we verify

NCT02108483

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phototoxicity Test of Dapsone Gel in Healthy Volunteers

Completed Phase 1 Last updated 5 October 2018

What this trial tests

Phase 1 trial testing dapsone gel in Healthy Volunteers in 33 participants. Completed in 1 May 2014.

Timeline

1 April 2014

Primary endpoint
1 May 2014

1 May 2014

Quick facts

Lead sponsor	Almirall, S.A.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	triple
Primary purpose	treatment
Enrollment	33
Start date	1 April 2014
Primary completion	1 May 2014
Estimated completion	1 May 2014
Sites	1 location across United States

Drugs / interventions tested

dapsone gel — full drug profile →
dapsone gel vehicle — full drug profile →

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Almirall, S.A. — full company profile →

Who can join

Adults 18 to 65, any sex, with Healthy Volunteers. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Phototoxicity Irritation Potential Using a Visual Scale
Time frame: 4 Days

Sponsor's own description

This study will evaluate the potential of dapsone gel and its vehicle to cause a phototoxic reaction following irradiation of the skin under controlled conditions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of dapsone gel

Trials testing the same drug.

NCT02959970 — Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris · Phase 4 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Almirall, S.A. trials

Trials by the same sponsor.

NCT07471932 — A Study of LAD106 in Healthy Adult Participants · Phase 1 · recruiting
NCT07311564 — A Study of LAD603 in Adults With Alopecia Areata · Phase 2 · recruiting
NCT06135415 — A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis · Phase 3 · completed
NCT06200597 — A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects · Phase 1 · completed
NCT05990725 — Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02108483 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Almirall, S.A.
Last refreshed: 5 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02108483.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing